Shiotsu Hiromichi, Okada Kazuhiro, Shibuta Tatsuki, Kobayashi Yuki, Shirahama Saki, Kuroki Chieri, Ueda Saori, Ohkuma Masanori, Ikeda Katsuyoshi, Ando Yukio, Matsui Hirotaka, Kayamori Yuzo, Umemura Tsukuru
Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Laboratory Medicine, Kumamoto University Hospital, Kumamoto, Japan.
Microrna. 2018;7(3):195-203. doi: 10.2174/2211536607666180709143335.
MicroRNAs (miRNA) are expected as useful biomarkers for various diseases. We studied the pre-analytical factors causing variation in the analysis of miRNA.
Blood samples were collected from 25 healthy subjects. Plasma and serum were obtained from the same samples. The levels of miR-451, -16, -126, and -223 were analyzed using RT-qPCR. Cel-miR-39 was added as a spiked-in control in each sample.
With the exception of miR-451, the levels of the miRNAs in plasma were higher than in serum. After high-speed centrifugation, the levels of miRNAs were almost equal between plasma and serum except for miR-451. Membrane filtration with 0.45 µm pore size reduced the levels of plasma miRNAs. The coagulation accelerators for serum processing did not affect the analysis of miRNA. The use of fraction containing particles of > 0.45 µm in size showed the inhibitory effect on the analysis of plasma miR-451. The RNase inhibitor was effective for protecting against the degradation of miRNAs.
Plasma contains factors modifying miRNA profiles. The immediate processing of plasma with membrane filtration and RNase inhibitor may be a relevant method for achieving the stable analysis of miRNA.
微小RNA(miRNA)有望成为各种疾病的有用生物标志物。我们研究了导致miRNA分析变异的分析前因素。
从25名健康受试者采集血样。从相同样本中获得血浆和血清。使用RT-qPCR分析miR-451、-16、-126和-223的水平。在每个样本中加入Cel-miR-39作为加标对照。
除miR-451外,血浆中miRNA的水平高于血清。高速离心后,除miR-451外,血浆和血清中miRNA的水平几乎相等。用孔径为0.45 µm的膜过滤可降低血浆miRNA的水平。用于血清处理的凝血促进剂不影响miRNA的分析。使用含有尺寸大于0.45 µm颗粒的级分对血浆miR-451的分析有抑制作用。RNase抑制剂对防止miRNA降解有效。
血浆含有改变miRNA谱的因素。用膜过滤和RNase抑制剂对血浆进行即时处理可能是实现miRNA稳定分析的一种相关方法。